In this context, and considering that the pathway has been successfully targeted in other human pathologies before (Parnell et al., 2015), we evaluated the inhibition of Epac/Rap1b by a natural extract as a potential therapeutic target for CD. Here, RAPGEF3 is linked to Cowden disease.